Skip to main content
Top
Published in: BMC Medical Imaging 1/2019

Open Access 01-12-2019 | Positron Emission Tomography | Research article

Development of a novel radioligand for imaging 18-kD translocator protein (TSPO) in a rat model of Parkinson’s disease

Authors: Chun-Yi Wu, Yang-Yi Chen, Jia-Jia Lin, Jui-Ping Li, Jen-Kun Chen, Te-Chun Hsieh, Chia-Hung Kao

Published in: BMC Medical Imaging | Issue 1/2019

Login to get access

Abstract

Purpose

The inflammation reaction in the brain may stimulate damage repair or possibly lead to secondary brain injury. It is often associated with activated microglia, which would overexpress 18-kDa translocator protein (TSPO). In this study, we successfully developed a new TSPO radioligand, [18F]-2-(4-fluoro-2-(p-tolyloxy)phenyl)-1,2-dihydroisoquinolin-3(4H)-one ([18F]FTPQ), and evaluate its potential to noninvasively detect brain changes in a rat model of Parkinson’s disease (PD).

Procedures

The precursor (8) for [18F]FTPQ preparation was synthesized via six steps. Radiofluorination was carried out in the presence of a copper catalyst, and the crude product was purified by high-performance liquid chromatography (HPLC) to give the desired [18F]FTPQ. The rat model of PD was established by the injection of 6-OHDA into the right hemisphere of male 8-week-old Sprague-Dawley rats. MicroPET/CT imaging and immunohistochemistry (IHC) were performed to characterize the biological properties of [18F]FTPQ.

Results

The overall chemical yield for the precursor (8) was around 14% after multi-step synthesis. The radiofluorination efficiency of [18F]FTPQ was 60 ± 5%. After HPLC purification, the radiochemical purity was higher than 98%. The overall radiochemical yield was approximately 19%. The microPET/CT images demonstrated apparent striatum accumulation in the brains of PD rats at the first 30 min after intravenous injection of [18F]FTPQ. Besides, longitudinal imaging found the uptake of [18F]FTPQ in the brain may reflect the severity of PD. The radioactivity accumulated in the ipsilateral hemisphere of PD rats at 1, 2, and 3 weeks after 6-OHDA administration was 1.84 ± 0.26, 3.43 ± 0.45, and 5.58 ± 0.72%ID/mL, respectively. IHC revealed that an accumulation of microglia/macrophages and astrocytes in the 6-OHDA-injected hemisphere.

Conclusions

In this study, we have successfully synthesized [18F]FTPQ with acceptable radiochemical yield and demonstrated the feasibility of [18F]FTPQ as a TSPO radioligand for the noninvasive monitoring the disease progression of PD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003;106(6):518–26.CrossRef Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003;106(6):518–26.CrossRef
2.
go back to reference McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38(8):1285–91.CrossRef McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38(8):1285–91.CrossRef
3.
go back to reference Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–97.CrossRef Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–97.CrossRef
4.
go back to reference Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. 2014;49(3):1422–34.CrossRef Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. 2014;49(3):1422–34.CrossRef
5.
go back to reference Guo Y, Kalathur RC, Liu Q, Kloss B, Bruni R, Ginter C, et al. Protein structure. Structure and activity of tryptophan-rich TSPO proteins. Science. 2015;347(6221):551–5.CrossRef Guo Y, Kalathur RC, Liu Q, Kloss B, Bruni R, Ginter C, et al. Protein structure. Structure and activity of tryptophan-rich TSPO proteins. Science. 2015;347(6221):551–5.CrossRef
6.
go back to reference Liu GJ, Middleton RJ, Hatty CR, Kam WW, Chan R, Pham T, et al. The 18 kDa translocator protein, microglia and neuroinflammation. Brain Pathol. 2014;24(6):631–53.CrossRef Liu GJ, Middleton RJ, Hatty CR, Kam WW, Chan R, Pham T, et al. The 18 kDa translocator protein, microglia and neuroinflammation. Brain Pathol. 2014;24(6):631–53.CrossRef
7.
go back to reference Streit WJ. Microglial response to brain injury: a brief synopsis. Toxicol Pathol. 2000;28(1):28–30.CrossRef Streit WJ. Microglial response to brain injury: a brief synopsis. Toxicol Pathol. 2000;28(1):28–30.CrossRef
8.
go back to reference Bribes E, Bourrie B, Casellas P. Ligands of the peripheral benzodiazepine receptor have therapeutic effects in pneumopathies in vivo. Immunol Lett. 2003;88(3):241–7.CrossRef Bribes E, Bourrie B, Casellas P. Ligands of the peripheral benzodiazepine receptor have therapeutic effects in pneumopathies in vivo. Immunol Lett. 2003;88(3):241–7.CrossRef
9.
go back to reference Ryu JK, Choi HB, McLarnon JG. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol Dis. 2005;20(2):550–61.CrossRef Ryu JK, Choi HB, McLarnon JG. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol Dis. 2005;20(2):550–61.CrossRef
10.
go back to reference Torres SR, Frode TS, Nardi GM, Vita N, Reeb R, Ferrara P, et al. Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation. Eur J Pharmacol. 2000;408(2):199–211.CrossRef Torres SR, Frode TS, Nardi GM, Vita N, Reeb R, Ferrara P, et al. Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation. Eur J Pharmacol. 2000;408(2):199–211.CrossRef
11.
go back to reference Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology. 2013;38(6):938–49.CrossRef Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology. 2013;38(6):938–49.CrossRef
12.
go back to reference Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21(2):404–12.CrossRef Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21(2):404–12.CrossRef
13.
go back to reference Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord. 2010;16(1):57–9.CrossRef Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord. 2010;16(1):57–9.CrossRef
14.
go back to reference Alam MM, Lee J, Lee SY. Recent Progress in the development of TSPO PET ligands for Neuroinflammation imaging in neurological diseases. Nucl Med Mol Imaging. 2017;51(4):283–96.CrossRef Alam MM, Lee J, Lee SY. Recent Progress in the development of TSPO PET ligands for Neuroinflammation imaging in neurological diseases. Nucl Med Mol Imaging. 2017;51(4):283–96.CrossRef
15.
go back to reference Varnas K, Cselenyi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, et al. PET imaging of [(11)C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. Eur J Nucl Med Mol Imaging. 2019;46(2):367–75.CrossRef Varnas K, Cselenyi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, et al. PET imaging of [(11)C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. Eur J Nucl Med Mol Imaging. 2019;46(2):367–75.CrossRef
16.
go back to reference Elkamhawy A, Park JE, Hassan AHE, Pae AN, Lee J, Park BG, et al. Design, synthesis, biological evaluation and molecular modelling of 2-(2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2H)-ones: a novel class of TSPO ligands modulating amyloid-beta-induced mPTP opening. Eur J Pharm Sci. 2017;104:366–81.CrossRef Elkamhawy A, Park JE, Hassan AHE, Pae AN, Lee J, Park BG, et al. Design, synthesis, biological evaluation and molecular modelling of 2-(2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2H)-ones: a novel class of TSPO ligands modulating amyloid-beta-induced mPTP opening. Eur J Pharm Sci. 2017;104:366–81.CrossRef
17.
go back to reference Zhou FC, Chiang YH, Wang Y. Constructing a new nigrostriatal pathway in the parkinsonian model with bridged neural transplantation in substantia nigra. J Neurosci. 1996;16(21):6965–74.CrossRef Zhou FC, Chiang YH, Wang Y. Constructing a new nigrostriatal pathway in the parkinsonian model with bridged neural transplantation in substantia nigra. J Neurosci. 1996;16(21):6965–74.CrossRef
18.
go back to reference Tournier I, Bernuau D, Poliard A, Schoevaert D, Feldmann G. Detection of albumin mRNAs in rat liver by in situ hybridization: usefulness of paraffin embedding and comparison of various fixation procedures. J Histochem Cytochem. 1987;35(4):453–9.CrossRef Tournier I, Bernuau D, Poliard A, Schoevaert D, Feldmann G. Detection of albumin mRNAs in rat liver by in situ hybridization: usefulness of paraffin embedding and comparison of various fixation procedures. J Histochem Cytochem. 1987;35(4):453–9.CrossRef
19.
go back to reference Scarf AM, Luus C, Da Pozzo E, Selleri S, Guarino C, Martini C, et al. Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa). Curr Mol Med. 2012;12(4):488–93.PubMed Scarf AM, Luus C, Da Pozzo E, Selleri S, Guarino C, Martini C, et al. Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa). Curr Mol Med. 2012;12(4):488–93.PubMed
20.
go back to reference Maia S, Arlicot N, Vierron E, Bodard S, Vergote J, Guilloteau D, et al. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. Synapse. 2012;66(7):573–83.CrossRef Maia S, Arlicot N, Vierron E, Bodard S, Vergote J, Guilloteau D, et al. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. Synapse. 2012;66(7):573–83.CrossRef
21.
go back to reference Vetel S, Serriere S, Vercouillie J, Vergote J, Chicheri G, Deloye JB, et al. Extensive exploration of a novel rat model of Parkinson's disease using partial 6-hydroxydopamine lesion of dopaminergic neurons suggests new therapeutic approaches. Synapse. 2019;73(3):e22077.CrossRef Vetel S, Serriere S, Vercouillie J, Vergote J, Chicheri G, Deloye JB, et al. Extensive exploration of a novel rat model of Parkinson's disease using partial 6-hydroxydopamine lesion of dopaminergic neurons suggests new therapeutic approaches. Synapse. 2019;73(3):e22077.CrossRef
22.
go back to reference Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T, et al. Extrastriatal spreading of microglial activation in Parkinson's disease: a positron emission tomography study. Ann Nucl Med. 2016;30(8):579–87.CrossRef Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T, et al. Extrastriatal spreading of microglial activation in Parkinson's disease: a positron emission tomography study. Ann Nucl Med. 2016;30(8):579–87.CrossRef
23.
go back to reference Koshimori Y, Ko JH, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF, et al. Imaging striatal microglial activation in patients with Parkinson's disease. PLoS One. 2015;10(9):e0138721.CrossRef Koshimori Y, Ko JH, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF, et al. Imaging striatal microglial activation in patients with Parkinson's disease. PLoS One. 2015;10(9):e0138721.CrossRef
24.
go back to reference Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, et al. Microglial activation in Parkinson's disease using [(18)F]-FEPPA. J Neuroinflammation. 2017;14(1):8.CrossRef Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, et al. Microglial activation in Parkinson's disease using [(18)F]-FEPPA. J Neuroinflammation. 2017;14(1):8.CrossRef
25.
go back to reference Israel I, Ohsiek A, Al-Momani E, Albert-Weissenberger C, Stetter C, Mencl S, et al. Combined [(18)F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice. J Neuroinflammation. 2016;13(1):140.CrossRef Israel I, Ohsiek A, Al-Momani E, Albert-Weissenberger C, Stetter C, Mencl S, et al. Combined [(18)F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice. J Neuroinflammation. 2016;13(1):140.CrossRef
26.
go back to reference Wang Y, Yue X, Kiesewetter DO, Niu G, Teng G, Chen X. PET imaging of neuroinflammation in a rat traumatic brain injury model with radiolabeled TSPO ligand DPA-714. Eur J Nucl Med Mol Imaging. 2014;41(7):1440–9.CrossRef Wang Y, Yue X, Kiesewetter DO, Niu G, Teng G, Chen X. PET imaging of neuroinflammation in a rat traumatic brain injury model with radiolabeled TSPO ligand DPA-714. Eur J Nucl Med Mol Imaging. 2014;41(7):1440–9.CrossRef
27.
go back to reference Awad M, Gavish M. Binding of [3H]Ro 5-4864 and [3H]PK 11195 to cerebral cortex and peripheral tissues of various species: species differences and heterogeneity in peripheral benzodiazepine binding sites. J Neurochem. 1987;49(5):1407–14.CrossRef Awad M, Gavish M. Binding of [3H]Ro 5-4864 and [3H]PK 11195 to cerebral cortex and peripheral tissues of various species: species differences and heterogeneity in peripheral benzodiazepine binding sites. J Neurochem. 1987;49(5):1407–14.CrossRef
28.
go back to reference Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1–5.CrossRef Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1–5.CrossRef
Metadata
Title
Development of a novel radioligand for imaging 18-kD translocator protein (TSPO) in a rat model of Parkinson’s disease
Authors
Chun-Yi Wu
Yang-Yi Chen
Jia-Jia Lin
Jui-Ping Li
Jen-Kun Chen
Te-Chun Hsieh
Chia-Hung Kao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Medical Imaging / Issue 1/2019
Electronic ISSN: 1471-2342
DOI
https://doi.org/10.1186/s12880-019-0375-8

Other articles of this Issue 1/2019

BMC Medical Imaging 1/2019 Go to the issue